肠道微生物群与肥胖:从微生物组到基于微生物的疗法概述。

Gut microbiota and obesity: an overview of microbiota to microbial-based therapies.

机构信息

Immunology Research Centre, Tabriz University of Medical Sciences, Tabriz, Iran.

Department of Microbiology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.

出版信息

Postgrad Med J. 2023 Jun 8;99(1171):384-402. doi: 10.1136/postgradmedj-2021-141311.

Abstract

The increasing prevalence of obesity and overweight is a significant public concern throughout the world. Obesity is a complex disorder involving an excessive amount of body fat. It is not just a cosmetic concern. It is a medical challenge that increases the risk of other diseases and health circumstances, such as diabetes, heart disease, high blood pressure and certain cancers. Environmental and genetic factors are involved in obesity as a significant metabolic disorder along with diabetes. Gut microbiota (GM) has a high potential for energy harvesting from the diet. In the current review, we aim to consider the role of GM, gut dysbiosis and significant therapies to treat obesity. Dietary modifications, probiotics, prebiotics, synbiotics compounds, using faecal microbiota transplant, and other microbial-based therapies are the strategies to intervene in obesity reducing improvement. Each of these factors serves through various mechanisms including a variety of receptors and compounds to control body weight. Trial and animal investigations have indicated that GM can affect both sides of the energy-balancing equation; first, as an influencing factor for energy utilisation from the diet and also as an influencing factor that regulates the host genes and energy storage and expenditure. All the investigated articles declare the clear and inevitable role of GM in obesity. Overall, obesity and obesity-relevant metabolic disorders are characterised by specific modifications in the human microbiota's composition and functions. The emerging therapeutic methods display positive and promising effects; however, further research must be done to update and complete existing knowledge.

摘要

肥胖和超重的患病率不断上升,这是全球范围内一个重大的公众关注问题。肥胖是一种涉及过多体脂肪的复杂疾病。它不仅是一个美容问题,还是一个医学挑战,增加了患其他疾病和健康状况的风险,如糖尿病、心脏病、高血压和某些癌症。环境和遗传因素与肥胖以及糖尿病等重大代谢紊乱有关。肠道微生物群(GM)具有从饮食中获取能量的巨大潜力。在本次综述中,我们旨在考虑 GM、肠道菌群失调和治疗肥胖症的重要疗法的作用。饮食改变、益生菌、益生元、合生元化合物、使用粪便微生物移植和其他基于微生物的疗法是干预肥胖症的策略,可以减少改善效果。这些因素中的每一个都通过各种机制发挥作用,包括多种受体和化合物来控制体重。临床试验和动物研究表明,GM 可以影响能量平衡方程的两个方面;一方面,作为影响饮食能量利用的因素,另一方面,作为调节宿主基因和能量储存和消耗的因素。所有调查的文章都表明 GM 在肥胖症中具有明确和不可避免的作用。总的来说,肥胖症和与肥胖相关的代谢紊乱的特点是人类微生物组的组成和功能发生特定的改变。新兴的治疗方法显示出积极和有前途的效果;然而,必须进行进一步的研究,以更新和完善现有的知识。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索